PubMed Health⌕ Search

Biomedical subjects

S N Pokrovskiĭ

Publications and source records attributed to S N Pokrovskiĭ.

At least 19 recordsLinked to original sources
PubMed2005

[Apolipoprotein B100 as a risk factor of acute coronary syndrome and this risk factor effect on arterial hypertension in patients with ischemic heart disease].

AIM: To clarify correlations between an elevated concentration of apolipoprotein B100 (apoB) in blood plasma and risk of acute coronary syndrome (ACS); to study apoB level in hypertensive patients and its correlation with ischemic heart disease (IHD) risk in these patients. MATERIAL AND METHODS: Lipid serum spectrum (cholesterol, triglycerides (TG), lipoprotein a (Lpa) and apoB was studied in 456 patients with ACS by NYHA criteria, 119 patients with chronic IHD and 86 patients free of cardiovascular diseases (controls). All 575 patients with IHD were divided into those with and without hypertension (426 and 149 patients, respectively). RESULTS: Lpa was significantly higher in patients with ACS; apoB was higher in ACS and chronic IHD patients. ApoB was higher in IHD normotensive patients than in controls and higher in IHD hypertensive patients than in IHD normotensive patients and in the control group. Lpa in IHD hypertensive patients was significantly higher (p < 0.045) than in the controls as well as TG (p < 0.05). By the other parameters the groups did not differ. CONCLUSION: The blood plasma level of apoB higher than 130 mg/dl is an independent and significant risk factor of ACS in IHD patients especially at the age under 60. The level of apoB over 115 mg/dl is a significant risk factor of IHD. The significance of this lipid factor rises in concomitant hypertension.

Acute Disease↗
PubMed2004

[Ethnic differences in apolipoprotein B levels in hyperlipidemia in Russian and Kirghiz populations].

AIM: To evaluate the levels of apolipoprotein B (apo-B) and coronary heart disease (CHD) risk factors in Russians and the Kirghiz with primary hyperlipidemia (PHL). MATERIAL AND METHODS: Lipid spectrum of the blood (LDLP and HDLP cholesterol, total cholesterol, triglycerides), apo-B, CHD risk factors were studied in 60 Russian and 75 Kirghis patients with PHL aged 28 to 67 years (mean age 50.0 +/- 7.59 years, 56 females and 79 males). RESULTS: In Russians a mean level of LDLP cholesterol and apo-B was significantly higher than in Kirghiz patients (3.95 +/- 1.29 mmol/l vs 3.51 +/- 1.17 mmol/l, p = 0.042; 173.3 +/- 57.3 mg/dl vs 145.5 +/- 49.3 mg/dl, p = 0.003, respectively). CHD in both ethnic groups occurred with similar rates. The multifactorial regression analysis shows that an apo-B concentration can serve an independent risk factor associated with CHD in the Kirghiz population (beta = 0.25, p = 0.03) while in Russians living in Kirghizia this factor is a low content of HDLP cholesterol (beta = -0.25, p = 0.05).

Adult↗
PubMed2002

[Method of quantitative analysis of beta2-microglobulin in human blood].

A simple and economic method of radial immunodiffusion is developed for diagnostic measurements of beta 2-microglobulin in human serum. Human serum and plasma concentrations of beta 2-microglobulin can be measured sufficiently accurately; the results are reproducible. The reproducibility and addictiveness of the method were evaluated. The error of the method is no more than 15% (3-36 mg/liter), which is permissible for methods of this type.

Humans↗
PubMed2002

[Effect of hormone replacement therapy on blood serum lipids in postmenopausal women with type 2 diabetes].

There are limited data concerning influence of hormone replacement therapy (HRT) on lipid profile in women with type 2 diabetes. Aim of the study was to compare changes of blood lipids during HRT in postmenopausal women with and without type 2 diabetes. Seventy seven women included in the study were assigned to 1 of 4 groups, basing on being diabetic or nondiabetic, and further subdivided into users of estrogen alone (ERT), and of estrogen plus progestin (EPRT). Effect of 6-month ERT (oral estradiol valerate 2 mg/day) and EPRT (oral estradiol valerate 2 mg/day sequentially combined with cyproterone acetate 1 mg/day) on total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides and lipoprotein (a) [Lp(a)] was separately assessed. EPRT and ERT caused decrease in LDL-C by 15% and 12%, and increase in HDL-C by 12% and 13%, respectively, in patients with diabetes (p<0.05 in all cases). LDL-C decreased by 11% and 15%, respectively, in women without diabetes (p<0.05 in all cases). Lp(a) was also reduced 25% with EPRT (p<0.01) and ERT (p<0.05). HDL-C increased 10% (p<0.05) with ERT but remained unchanged with EPRT. In conclusion, changes in all lipid parameters except Lp(a) caused by ERT and EPRT were comparable in postmenopausal women with and without type 2 diabetes.

Aged↗
PubMed2002

[Apheresis of immunoglobulins - new approach to the treatment of severe dilated cardiomyopathy].

Two courses of immunoadsorption with 'Ig Adsopak' were used in the treatment of a patient with dilated cardiomyopathy (DCM) during which all class G and partially class M and A immunoglobulins were removed. Every course consisted of 5 daily procedures and resulted in removal of 98% of immunoglobulins. This was associated with complete removal of autoantibodies to beta1-adrenoreceptor. After the end of a course loss of immunoglobulins was replenished by intravenous infusion of Pentaglobin and Oktagam. Echocardiographic study carried out before, during and after second course of apheresis revealed reduction of left and right ventricular and atrial volumes and dimensions, improvement of contractility of anterior part of interventricular septum and of anterolateral left ventricular wall. As efficacy of drug therapy of dilated cardiomyopathy is low and facilities of cardiac transplantation are limited the method of therapeutic apheresis reveals novel perspectives of the treatment of dilated cardiomyopathies.

Blood Component Removal↗
PubMed2002

[Lipoprotein (a) and ischemic heart disease in patients with hypertensive disease].

Relationship between level of lipoprotein (a) and presence of ischemic heart disease (IHD) was studied in 191 patients with hypertensive disease (essential hypertension) (112 men, 79 women, age 56.9-/+10.6 years) and 33 patients with normal blood pressure (23 men, 10 women, age 50.8-/+11.0 years). Concentration of lipoprotein (a) in men with hypertension and IHD (n=62) was significantly higher than in men with hypertension without IHD (n=50) (median 19 and 9 mg/dl, respectively, p=0.02). Women with hypertension and with (n=23) and without (n=56) IHD had similar blood levels of lipoprotein (a) (median 13 and 15 mg/dl, respectively, p=0.89). Difference in lipoprotein (a) levels between patients with hypertensive disease and those with normal blood pressure was not significant (median 14 and 10 mg/dl, respectively, p=0.50).

Adult↗
PubMed2002

[Lipoprotein(a) and Apo-A isoforms in patients with intermittent claudication].

AIM: To study a correlation between lipoprotein(a) [LP(a)], as well as the phenotype of apoprotein(a) [apo(a)] and the presence of intermittent claudication (IC). MATERIALS AND METHODS: The study included 25 patients (9 females, 16 males; mean age, 63.4 +/- 8.2 years) and 50 individuals (21 females, 29 males; mean age, 61.3 +/- 6.1 years) of a control group. RESULTS: In the patients, the level of LP(a) was 3 times higher than in the controls (median 39 and 13 mg/dl, respectively; p < 0.01). The low molecular-weight phenotypes of apo(a) occurred significantly more frequently in the patients than those in the controls (62 and 28%, respectively; p = 0.02). CONCLUSION: Multifactorial analysis has shown that the level of Lp(a) is an independent and important factor associated with the presence of IC.

Aged↗
PubMed2000

[Association of lipoprotein(a) and apolipoprotein(a) phenotypes with coronary and carotid atherosclerosis in CHD men].

AIM: To evaluate in a case-control cross-sectional study whether lipoprotein(a) concentration and apo(a) phenotypes are associated with the presence and severity of coronary and carotid atherosclerosis. MATERIALS AND METHODS: We have examined 198 male CHD patients (mean age 53 +/- 8) years) with stenosis more than 50% at least in one main coronary artery or its major branches. Duplex scanning was performed in 168 patients to assess the degree of carotid atherosclerosis. Seventy six apparently healthy men (mean age 39 +/- 9 years) formed the control group. Lp(a) concentration was measured by ELISA, apo(a) phenotyping was performed by immunoblotting. RESULTS: Lp(a) level was significantly higher in cases compared to controls: 37 +/- 31 mg/dl vs. 18 +/- 27 mg/dl, p < 0.05. Patients had low-molecular weight apo(a) phenotypes more frequently than controls: 46% vs. 29%, p = 0.01. Patients aged 45 years and younger had low-molecular weight apo(a) phenotypes more frequently than older ones (65% vs. 42%, p < 0.05) and controls (65% vs. 29%, respectively, p = 0.001). High Lp(a) level and low-molecular weight apo(a) phenotypes correlated with presence and number of coronary occlusions. CONCLUSION: There was association between Lp(a) level, low-molecular weight apo(a) phenotypes and presence, severity, extension of carotid atherosclerosis. No differences in distribution of other CHD risk factors among all subgroups of patients were found.

Adult↗
PubMed1997

[Lipoprotein(a) as a biochemical marker of coronary atherosclerosis].

The relation between lipoprotein Lp(a) levels, other lipids and severity of coronary atherosclerosis was studied in 281 patients (241 men and 40 women aged 24 to 68 years) with suspected or diagnosed coronary heart disease. All of them underwent coronary angiography. The angiograms were evaluated according to two scores: vessel score (0 to 3 points for 0 to 3 vessels with stenoses > 50%) and stenosis score (0 to 32 points, number and severity of coronary lesions). 224 patients with verified coronary atherosclerosis were grouped according to these scores and compared with subgroup of 57 patients with intact coronary arteries. Lp(a) levels were significantly higher in patients with 1-, 2- (p < 0.05) and 3-vessel (p < 0.01) disease and stenosis score more than 10 points (p < 0.01). LDL cholesterol (LDL-C) levels were significantly higher in patients with 2- and 3-vessel disease and stenosis score more than 10 points (p < 0.05 in all cases). There was a positive correlation between Lp(a) levels and severity of coronary atherosclerosis (p < 0.05). Lp(a) contributes < 15% of total plasma cholesterol (TC). After subtraction of Lp(a)-cholesterol from TC according to modified Friedewald formula there was no any correlation between Lp(a) and LDL-C levels.

Adult↗
PubMed1993

[Atherosclerosis of the major arteries of the head and the content of lipoprotein(a) in the blood plasma].

It is established that atherosclerotic patients with impaired major arteries of the head have high concentration of blood lipoprotein (a) following ischemic disorder of cerebral circulation. Irrespectively of the clinical picture, atherosclerosis of the major head arteries correlated in severity with blood levels of lipoprotein (a). It is suggested that lipoprotein (a) can serve an essential biochemical marker of major head arteries atherosclerosis.

Acute Disease↗
PubMed1992

[Use of immunosorption for selective decrease of lipoprotein (A) levels in patients with coronary atherosclerosis].

Lipoprotein (a) [L(a)] is an atherogenic lipoprotein, its human plasma concentration correlates with the occurrence of coronary heart disease. The procedure for selectively removing L(a) with an anti-L(a) immunosorbent was performed to treat 3 patients who had high L(a), normal total cholesterol and other lipoprotein levels. All the patients had coronary stenosis as documented by angiography. After L(a)-apheresis, the level of L(a) decreased by 72%, while that of other plasma components, including low density lipoproteins virtually unchanged. Thus, the procedure of L(a)-apheresis is an effective and safe method for lowering human blood L(a) concentrations. In addition, this in vivo model allows information on L(a) metabolism to be obtained.

Adult↗
PubMed1992

[A comparison of 3 methods of lipoprotein (a) isolation from human plasma].

Three methods for purification of lipoprotein (a) [Lp(a)] from human plasma were compared. Method I: two-stage ultracentrifugation with subsequent gel-filtration of Lp(a) containing fractions (1.063-1.090 g/ml) on Sepharose CL-4B. Method II: ultracentrifugation followed by affinity chromatography of plasma fraction (1.063 g/ml) on anti-apoB sorbent. Method III: affinity chromatography of the whole plasma on anti-apo(a) sorbent. The Lp(a) yield of these methods is 35, 54 and 41%, respectively. The method III is preferable of these three because it permitted high purification of a large amount of Lp(a) by single-step chromatography.

Chromatography, Affinity↗